Solve this question paper. Use latest medical guidelines and evidences. Don't write long sentances. Give maximum answers in tables, flowchart and diagrams.
endometrial cancer risk classification ESGO ESMO 2021
PORTEC-4a trial endometrial cancer adjuvant treatment
platinum resistant ovarian cancer treatment bevacizumab
Keynote-A18 cervical cancer chemoradiotherapy pembrolizumab
PARP inhibitor recurrent ovarian cancer olaparib niraparib rucaparib
HIPEC ovarian cancer first line randomized trial OVHIPEC
uterine sarcoma classification management WHO 2020
ESGO ESMO 2021 endometrial cancer risk classification molecular TCGA groups
endometrial cancer risk classification molecular groups adjuvant treatment
HIPEC ovarian cancer randomized trial survival
mirvetuximab soravtansine SORAYA MIRASOL platinum resistant ovarian cancer FDA 2022 2023
WHO screening program criteria Wilson Jungner uterine sarcoma classification embryonal rhabdomyosarcoma treatment 2024
brachytherapy advances IGBT MRI guided adaptive ABS GEC-ESTRO 2023 radiation complications management
HIPEC ovarian cancer perioperative complications systematic review
WHO analgesic ladder cancer pain 2022 2023 update step 2 debate malignant bowel obstruction management
Quick Answer Summary
| Q | Topic | Key Evidence Used |
|---|---|---|
| Q1 | EC risk classification + PORTEC-4a | ESGO/ESTRO/ESP 2021; PORTEC-4a (Lancet Oncol 2026, PMID 41449145) |
| Q2 | Platinum-resistant OC | MIRASOL/SORAYA (mirvetuximab FDA 2024); AURELIA (bevacizumab); NCCN 2024 |
| Q3 | WHO ladder + MBO | Fallon 2-step RCT (Ann Oncol 2022); ESMO MBO guidelines |
| Q4 | CCRT rationale + KEYNOTE-A18 | KEYNOTE-A18 PFS (Lancet 2024, PMID 38521086) + OS (Lancet 2024, PMID 39288779) |
| Q5 | HRD/PARPi mechanism + evidence | SOLO-2, NOVA, ARIEL3; Meta-analysis PMID 38409030 (J Ovarian Res 2024) |
| Q6 | WHO screening criteria | Wilson-Jungner 10 criteria; sensitivity/specificity/PPV/NPV framework |
| Q7 | Uterine sarcoma + adolescent ERMS | WHO 2020 classification; IRS/EpSSG VAC protocol |
| Q8 | Brachytherapy advances + complications | IGABT/EMBRACE protocol; GEC-ESTRO 2023; QUANTEC constraints |
| Q9 | HIPEC evidence + complications | OVHIPEC-1 final (PMID 37708912); CHIPOR (PMID 39549720); HORSE trial |
| Q10 | EOL care + bony pain | Single-fraction RT 8Gy; Zoledronic acid/Denosumab; KEYNOTE-826 |